PA21 Safety and Efficacy in Adult Chinese Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 286 participants.
Also called NCT03644264
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 286 participants
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
- Registry
-
NCT03644264
-
- Other papers using this trial's data
- Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03644264. Randomized; no masking; primary purpose treatment. Start 2018-08-31 (actual); primary completion 2020-08-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PA21 Safety and Efficacy in Adult Chinese Subjects
- Condition
- Chronic Kidney Disease Requiring Chronic Dialysis
- Condition
- Hyperphosphatemia
- Intervention (Drug)
- PA21
- Intervention (Drug)
- sevelamer carbonate
- Lead sponsor
- Vifor Fresenius Medical Care Renal Pharma
Record details
- Record id
cardio:ct-nct03644264- Content hash
b4da559590ae970f5999828a34176d2968b705d467b542d4b742d6584875f036